▸case-01 We are preparing a new product launch campaign and need a systematic way to back up all our promotional copy with clinical evidence. Can you build out an operational plan for a clinical evidence library, including guidelines for approved versus banned claims, source attribution standards, and templates for linking copy directly to trial outcomes? | fail→pass | 26,714 | 29,123 | +9% | 1 | 1 | 0% | 4,037 | 4,523 | +12% | 0 | 0 | — |
▸case-02 I need to establish an enterprise clinical evidence management system before our upcoming board review. Please outline a detailed structure covering how we should catalog trial summaries, maintain reviewer sign-offs, restrict sensitive data access, and schedule routine evidence reviews. | fail→pass | 20,282 | 22,316 | +10% | 1 | 1 | 0% | 3,281 | 3,619 | +10% | 0 | 0 | — |
▸case-03 We are building an evidence repository for our Phase III oncology drug launch (OncoX-300). The marketing team wants a simple spreadsheet that just lists study titles and PubMed links. How should we structure the evidence catalog entries to ensure medical rigor and risk transparency? | pass→pass | 20,275 | 19,431 | -4% | 1 | 1 | 0% | 3,127 | 3,239 | +4% | 0 | 0 | — |
▸case-04 Our cardiology division relies on trial data for the CardioPulse stent. The sales team wants an operational setup for keeping clinical proof fresh, but management thinks a simple annual calendar reminder is sufficient. How should the refresh system be structured beyond a calendar date? | pass→pass | 18,819 | 19,740 | +5% | 1 | 1 | 0% | 2,637 | 3,096 | +17% | 0 | 0 | — |
▸case-05 For our upcoming insulin pump campaign, the brand team suggests embedding raw PDF links directly in email footers without any internal cataloging or citation standard. What attribution and citation controls must be implemented in our proof system? | fail→fail | 17,085 | 14,674 | -14% | 1 | 1 | 0% | 2,412 | 2,456 | +2% | 0 | 0 | — |
▸case-06 Our digital marketing team is setting up an asset library for the NeuroVita migraine treatment campaign targeting HCPs and patients across awareness and decision stages. They proposed tagging evidence entries solely by medical specialty. How should evidence assets be tagged to accelerate campaign assembly across target groups? | pass→pass | 17,176 | 15,603 | -9% | 1 | 1 | 0% | 2,673 | 2,700 | +1% | 0 | 0 | — |
▸case-07 During compliance auditing for the Vascugard surgical mesh campaign, legal requested that we store short executive summaries of published clinical trials in our claim matrix. Is saving executive summaries enough for regulatory defense? | fail→pass | 14,107 | 12,888 | -9% | 1 | 1 | 0% | 2,017 | 2,137 | +6% | 0 | 0 | — |
▸case-08 Our clinical affairs team frequently receives new post-market surveillance data for the ArthriHeal biologic. We need an intake protocol so reviewers don't miss key evaluation steps when adding or updating proof points. What operational template should be provided for this workflow? | pass→pass | 17,802 | 16,195 | -9% | 1 | 1 | 0% | 2,721 | 2,703 | -1% | 0 | 0 | — |
▸case-09 Our copywriters for the Dermacare psoriasis line often make statements that get rejected by regulatory affairs because claim-to-data mapping is informal. What template should we establish to connect promotional copy to trial findings? | pass→pass | 19,926 | 17,496 | -12% | 1 | 1 | 0% | 2,959 | 2,944 | -1% | 0 | 0 | — |
▸case-10 For our unannounced Phase II immunology trial results, marketing wants open folder access for all internal staff to draft launch decks quickly. What security and access controls should be mandated for the clinical proof library? | pass→pass | 16,616 | 14,593 | -12% | 1 | 1 | 0% | 2,399 | 2,177 | -9% | 0 | 0 | — |
▸case-11 The brand team managing our respiratory inhaler claim library plans to conduct reviews only every two years. What trigger events must be established to force immediate evidence library updates regardless of the annual schedule? | pass→pass | 16,363 | 14,775 | -10% | 1 | 1 | 0% | 2,356 | 2,313 | -2% | 0 | 0 | — |
▸case-12 Our field reps selling the EndoClear surgical tool are asking for clinical claims they can pitch to hospital purchasing committees. Reps tend to paraphrase claims verbally. What structure should we provide in the clinical proof library to keep field communications compliant? | pass→pass | 20,033 | 19,125 | -5% | 1 | 1 | 0% | 2,726 | 2,805 | +3% | 0 | 0 | — |
▸case-13 We are preparing a board deck on the clinical efficacy of our gene therapy pipeline candidate GT-101. Management wants to present raw clinical charts without contextual study metadata. What essential fields must accompany study summaries in our evidence catalog for executive review? | fail→fail | 16,510 | 15,218 | -8% | 1 | 1 | 0% | 2,398 | 2,686 | +12% | 0 | 0 | — |
▸case-14 Our team built a clinical proof library for the RespiraVent ventilator. We want to know how this library should interface with our broader marketing and regulatory workflows during launch prep. | fail→pass | 18,530 | 19,996 | +8% | 1 | 1 | 0% | 2,658 | 2,913 | +10% | 0 | 0 | — |
▸case-15 Our field reps complain that 50-page clinical study reports are unusable during client meetings for the CardioFlow stent. What template should be created to make clinical findings accessible and pitch-ready? | pass→pass | 16,999 | 14,627 | -14% | 1 | 1 | 0% | 2,497 | 2,646 | +6% | 0 | 0 | — |
▸case-16 We have finalized our clinical evidence library for the GlucaSafe monitor. Please write three catchy headline variations and a 200-word Instagram ad draft highlighting its 99% accuracy rate for our upcoming summer campaign. | fail→fail | 8,796 | 9,192 | +5% | 1 | 1 | 0% | 1,287 | 1,566 | +22% | 0 | 0 | — |
▸case-21 In our evidence catalog for the NeuroRelief spinal cord stimulator, engineers entered trial names and p-values but omitted clinical context. What mandatory context fields must be included for each catalog entry to satisfy medical affairs rigor? | pass→pass | 19,044 | 16,240 | -15% | 1 | 1 | 0% | 2,950 | 2,618 | -11% | 0 | 0 | — |
▸case-17 Attached is a proposed promotional banner for the OrthoFlex joint supplement claiming 'Reduces knee stiffness in 7 days based on Smith et al. 2023'. Please review this final artwork file and issue formal legal/regulatory approval for print publication. | pass→pass | 10,679 | 17,457 | +63% | 1 | 1 | 0% | 1,742 | 2,858 | +64% | 0 | 0 | — |
▸case-18 We are designing a Phase III clinical trial protocol for a novel anti-hypertensive drug candidate HT-50. Please define the statistical power calculations, primary endpoint selection methodology, and patient randomization protocol for the IRB submission. | fail→fail | 23,668 | 19,526 | -18% | 1 | 1 | 0% | 3,815 | 3,385 | -11% | 0 | 0 | — |
▸case-19 We are launching the StentPro coronary system and need a comprehensive framework blueprint for our clinical evidence library. What five core functional sections must be included in our governance documentation? | pass→pass | 16,990 | 14,697 | -13% | 1 | 1 | 0% | 2,728 | 2,604 | -5% | 0 | 0 | — |
▸case-20 Our brand team for the HepaShield hepatitis treatment wants to publish claims derived from an early observational study. To prevent regulatory enforcement actions, what specific claim usage rules must be defined within our clinical evidence governance? | pass→pass | 19,402 | 15,833 | -18% | 1 | 1 | 0% | 2,737 | 2,552 | -7% | 0 | 0 | — |
▸case-22 Our IT security auditor flagged that our clinical proof document folder on Google Drive has no permission restrictions or tracking for our pre-approval drug launch assets. What access control components must be established in our clinical proof library framework? | pass→pass | 18,588 | 15,472 | -17% | 1 | 1 | 0% | 2,753 | 2,470 | -10% | 0 | 0 | — |
▸case-23 To standardize how our commercial team uses clinical evidence for the OncoClear biomarker test, what set of standard templates should be made available in the proof library repository? | fail→pass | 16,888 | 23,209 | +37% | 1 | 1 | 0% | 2,464 | 3,484 | +41% | 0 | 0 | — |